间充质干细胞作为2型糖尿病补充疗法有效性及安全性的Meta分析OA

Objective To investigate the efficacy and safety of mesenchymal stem cells(MSC)in the treatment of type 2 diabetes mellitus(T2DM)at multiple time points using Meta-analysis,and to explore whether MSC therapy can be used as a complementary treatment for T2DM.Methods Two researchers independently con-ducted literature searches in PubMed,Web of Science,Cochrane Library,CNKI,Wanfang Database,and The Chinese Biomedical Literature Database.Studies were screened and data extracted according to inclusion and exclusion criteria.Meta-analysis was performed using RevMan 5.4 software.Results A total of 11 clinical trials on MSC treatment for T2DM were included in this study.Compared to baseline,significant reductions in glycated hemoglobin(HbA1c,MD:-1.12,95%CI:[-1.67,-0.57];MD:-1.34,95%CI:[-2.10,-0.57];MD:-1.06,95%CI:[-1.68,-0.45])and exogenous insulin dosage(MD:-22.68,95%CI:[-29.89,-15.47];MD:-25.34,95%CI:[-38.41,-12.26];MD:-27.45,95%CI:[-36.65,-18.24])were observed at 3,6,and 12 months post-treatment(P<0.01).Fasting blood glucose(FBG,MD:-1.10,95%CI:[-2.10,-0.10])and fasting C-peptide(MD:0.48,95%CI:[0.06,0.90])showed significant improvement only at 6 months post-treatment(P<0.05).Compared to the control group,the exogenous insulin dosage was significantly reduced at 3,6,and 12 months post-treatment(MD:-15.58,95%CI:[-18.26,-12.89];MD:-16.77,95%CI:[-30.09,-3.46];MD:-26.90,95%CI:[-29.59,-24.20],P<0.01).HbA1c showed significant reductions at 6 and 12 months post-treatment(MD:-0.62,95%CI:[-1.15,-0.09];MD:-0.75,95%CI:[-1.40,-0.11],P<0.05),and FBG showed significant reduction at 6 months post-treatment(MD:-0.83,95%CI:[-1.57,-0.09],P<0.05).The source of MSC(autologous/allogeneic)might be one of the factors contributing to the heterogeneity in HbA1c and FBG.No serious adverse reactions related to MSC treatment were reported,with common adverse reactions being transient fever and hypoglycemic events.Conclusion MSC treatment demonstrated a signifi-cant control over blood glucose levels and exogenous insulin dosage in T2DM patients across multiple time points,with a favorable safety profile.MSC therapy can be considered as a complementary treatment option for T2DM.